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Background: Dermatofibrosarcoma protuberans (DFSP) is a tumor of intermediate malignancy,
which in selected circumstances can pose difficulty in diagnosis. Clear cell sarcoma (CCS) is a very
rare aggressive soft tissue sarcoma that can be difficult to distinguish histologically from melanoma.
Methods: The current literature on t(17;22) COL1A1-PDGFB fluorescence in situ hybridization
(FISH) assay in DFSP was reviewed. Also reviewed was the current literature on dual color break-
apart EWSR1 FISH assay in CCS. Finally, the current utilization patterns of these tests was assessed
in attendees of the American Society of Dermatopathology annual meeting (Chicago, 2016).
Results: The literature indicates that (17;22) COL1A1-PDGFB FISH assay has limited value for
classic DFSP, where the diagnosis can be established by routine morphology and immunohisto-
chemistry. Given the high specificity of the EWSR1 FISH assay and significant complexity in the
diagnosis of CCS, this ancillary study is helpful in distinguishing CCS from melanoma.
Conclusions: In attendees, t(17;22) COL1A1-PDGFB FISH testing for classic cases of DFSP is
appropriately not being used by respondents. However, the literature sustains that it is useful in
selected circumstances in which a definitive diagnosis is challenging. The majority of respon-
dents are utilizing the EWSR1 FISH assay to distinguish CSS from melanoma as is supported by
the literature.
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1 | INTRODUCTION
Appropriate use criteria (AUC) combine the best scientific evidence
available with the collective judgment of experts to yield a statement
of the appropriateness of performing a particular ancillary test in spe-
cific clinical scenarios encountered in everyday practice. In 2015, the
American Society of Dermatopathology (ASDP) created the AUC Task
Force to help guide dermatopathologists in their use of ancillary tests.
Four subgroups were established and each group chose two to three
ancillary studies for which to develop AUC. This review provides a
synopsis of the best scientific evidence (literature review) for the
ancillary studies chosen by the “Soft Tissue” subgroup: t(17;22)
COL1A1-PDGFB fluorescence in situ hybridization (FISH) for the diag-
nosis of dermatofibrosarcoma protuberans (DFSP) and EWSR1 breaka-
part FISH in differentiating melanocytic tumors from clear cell
sarcoma (CCS). In addition, a summary of the current clinical practice
from a group of attendees at the 53rd Annual Meeting of the ASDP
(Chicago, 2016) is presented.
1.1 | t(17;22) COL1A1-PDGFB FISH for diagnosis
of DFSP
DFSP is a distinctive slow-growing dermal and subcutaneous tumor of
intermediate malignancy. Patients are typically in their early or middle
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adulthood. Tumors have a predilection for the trunk, proximal extrem-
ities, and head/neck region.1 Grossly, the tumor appears as a well-
circumscribed gray-white nodule involving the dermis and subcutis.
Microscopically, despite its apparent gross circumscription, the tumor
diffusely infiltrates the dermis and subcutis. DFSP is composed of uni-
form monomorphic spindle cells arranged in a distinctive storiform or
cartwheel pattern. There is little nuclear pleomorphism and no signifi-
cant mitotic activity.2 By immunohistochemistry DFSP typically
expresses CD34 and is negative for factor XIIIa and S100 protein.
The most common and challenging differential diagnoses for
DFSP are represented by the deep and cellular variants of dermatofi-
broma. In contrast to cellular dermatofibroma, DFSP is characterized
by a larger size, infiltrative pattern within the subcutis and uniform
morphology while typically lacking secondary elements such as giant
cells, xanthoma cells, or inflammatory cells. Another common differen-
tial diagnosis is the diffuse variants of neurofibroma. In this case, the
lower cellularity and positive staining for S100 seen in neurofibroma
allows for the differentiation from DFSP.3 Variations from the classic
histology are seen in pigmented DFSP (Bednar tumor) and DFSP with
areas of fibrosarcomatous change. Uncommon histologic variants
include DFSP with myxoid changes, which may cause confusion with
a myxoid liposarcoma, DFSP with areas of undifferentiated pleomor-
phic sarcoma, DFSP resembling a vascular tumor, DFSP with myoid
nodules, and the sclerotic variant of DFSP.3–7
DFSP is a tumor of intermediate malignancy with low metastatic
potential, but locally aggressive behavior. Historically, recurrence
rates are reported to be as high as 50%; however, more recent stud-
ies show an overall recurrence rate of 7.3%.8,9 The presence of
fibrosarcomatous areas indicates a more aggressive behavior with
higher potential for metastasis.10 Wide local excision is the treat-
ment of choice.
Cytogenetically, DFSP is characterized by a balanced or unbal-
anced t(17;22)(q22;q13) translocation or a supernumerary ring chro-
mosome, resulting in the fusion of exon 2 of PDGFB gene encoding
the platelet-derived growth factor beta with various exons (from 6 to
47) of COL1A1 gene encoding the alpha chain type 1 collagen.11–14
Interestingly, the same rearrangement was demonstrated in giant cell
fibroblastoma (GCF), a tumor developing in children that is now con-
sidered to represent a juvenile form of DFSP.15 The ring chromosome
is more common in adult cases of DFSP while the linear translocation
tends to occur in children and is prevalent in GCF.14,15 The transloca-
tion deletes exon 1 of PDGFB and puts the gene under control of the
COL1A1 gene promoter, compromising the physiological regulation of
this factor. This results in overexpression of PDGFB, which enables
downstream signaling through the PDGFB receptor and MAP-kinase
pathway.13 In addition, this alteration renders the tumor sensitive to
imatinib mesylate, which is now used for the treatment of inoperable
or metastatic disease.16–18
The t(17;22) translocation is specific for DFSP; therefore, its
detection can potentially be used as an ancillary diagnostic tool in
cases with unusual histology or atypical clinical presentation.
Another potential use is to identify cases that are susceptible to ima-
tinib therapy. Several methods can be employed to detect the trans-
location including conventional cytogenetics, dual fusion COL1A1/
PDGFB FISH, PDGFB or COL1A1 break-apart FISH, reverse-
transcriptase polymerase chain reaction (RT-PCR) with primers flank-
ing the translocation breakpoint, and next generation sequencing
(NGS). This review focuses on FISH methods for the detection on
the genomic rearrangements characteristic for DFSP. The dual fusion
FISH test uses two distinctly labeled probes, usually red and green,
which span the COL1A1 gene on chromosome 17q21.33 and PDGFB
gene on chromosome 22q13.1. The presence of a rearrangement
resulting in a fusion is manifested by the occurrence of a yellow sig-
nal. A normal cell shows two red and two green signals per nucleus.
A reciprocal balanced translocation shows two yellow fusion signals,
one red, and one green signal per nucleus. Of note, in addition to
the expected pattern associated with a reciprocal t(17;22) transloca-
tion (two yellow fusion signals, one red, and one green signal), a sig-
nificant number of DFSP cases show atypical patterns characterized
by numerous yellow fusion signals (3-10) and extra copies of both
green (PDGFB—2 to 8) and red (COL1A1—3 to 10) signals (Figure 1).
This is caused by the presence of a ring chromosome containing
multiple copies of the rearranged genomic material.19 The PDGFB
and COL1A1 break-apart FISH employs dual color probes (red and
green) which flank the PDGFB and COL1A1 gene, respectively. A nor-
mal cell shows two yellow fusion signals. The presence of a rearran-
gement is manifested in a split of the red and green signals. A probe
is considered to be split when the distance between the red and
green signal is two times the size of a hybridization signal. Similar to
the fusion probe, in addition to the expected pattern associated with
balanced t(17;22) translocation (one yellow fusion signal, one red,
and one green signal), a significant number of DFSP cases show
atypical patterns which include one or multiple copies (from 2 to 5)
of the 50 telomeric region of COL1A1 gene or 30 centromeric seg-
ment of PDGFB gene indicating unbalanced rearrangements.15,20
FIGURE 1 Dual fusion interphase fluorescence in situ hybridization
(FISH) conducted on a dermatofibrosarcoma protuberans (DFSP) with
a custom probe set spanning the COL1A1 (spectrum orange) and the
PDGFB (spectrum green) loci shows multiple juxtaposed orange/green
(yellow) signals indicative of multiple copies of COL1A1/PDGFB fusion
(×200, courtesy of Julia Bridge, MD)
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1.2 | EWSR1 breakapart FISH in differentiating
melanocytic tumors from CCS
CCS (malignant melanoma of soft parts) was initially described by
Enzinger in 1965 and is a very rare aggressive soft tissue sarcoma
showing neuroectodermal and melanocytic differentiation.21,22
Although it shares clinical, histologic, immunohistochemical, molecular,
and ultrastructural features with melanoma, CCS is considered to be a
distinct entity that is separate from cutaneous melanoma.23–25 Dis-
tinction between these two entities is crucial as the treatment modal-
ity and prognosis are different. CCS typically occurs in adolescents
and young adults (third to fourth decades of life) with a slight female
predominance and preferentially arises in the deep soft tissue of ten-
dons, aponeuroses, and fascial structures of the distal extremities. It is
associated with a high propensity for multiple local recurrences with
late metastases and a high death rate.26–28 It is one of the few sarco-
mas with a high propensity for lymph node metastases, which are pre-
sent in up to 50% of cases.29 Histologically typical cases of CCS are
characterized by a nested or fascicular growth pattern of fusiform
and/or epithelioid cells with clear to finely granular cytoplasm and
prominent nucleoli.30 Delicate fibrous septa encase the cellular aggre-
gates and in two thirds of cases multinucleated cells are observed.31
Immunohistochemically, virtually all CCSs express S100 protein dif-
fusely and most are also positive for Melan-A, HMB45, and MiTF sim-
ilar to cutaneous melanomas.30 Melanin pigment can be detected
either by hemotoxylin and eosin (H&E) or with appropriate histochem-
ical stains (eg, Fontana-Masson) and melanosomes can be seen in
varying stages of development using electron microscopy.32 BRAF/
NRAS mutations, which are present in ~50% to 60% of melanomas,
have also been rarely detected in CCSs.33,34 Superficial cutaneous
examples are well documented in the literature.31,35,36 In these
instances, the tumor is dermal-based with potential subcutaneous
extension. In addition, rare cases with a junctional component mimick-
ing melanoma in situ have also been reported.37,38 Consequently, CCS
can be confused with cutaneous spindle-cell melanoma or metastatic
melanoma, with significant prognostic and predictive repercussions
for the patient.
CCS has a characteristic translocation that most commonly fuses
EWSR1 on chromosome 22 with activating transcription factor-1
(ATF1) gene on chromosome 12 t(12;22)(q13;q12) resulting in four
fusion transcripts39. Less commonly EWSR1 is fused with CREB1 on
chromosome 2 t(2;22)(q34;q12). The chimeric protein functions as a
potent constitutive activator and mimics the action of melanocyte
stimulating hormone by binding to and constitutively activating the
promoter for MITF, the melanocyte master transcription factor.40
Many methods for diagnosis are based on the aforementioned molec-
ular characteristics, including classic cytogenetics, RT-PCR, FISH, and
NGS. Although EWSR1 is a promiscuous gene associated with a num-
ber of sarcomas, carcinomas and very recently reported in a subset of
malignant mesotheliomas41 and in a group of acral fibroblastic spindle
cell neoplasms,42 its rearrangement has never been reported in cuta-
neous melanomas. Consequently, a dual-color break-apart EWSR1
FISH probe, which is commercially available and allows for detection
in formalin-fixed paraffin-embedded tissues, can potentially serve as a
very useful ancillary tool to support the diagnosis of CCS in
challenging cases. It could also conceivably be used to distinguish CCS
from benign melanocytic proliferations that mimic melanoma, such as
cellular blue nevus.
The commercially available probe spans the known common
breakpoints in the EWSR1 (introns 7-10). A probe specific for the
3 (telomeric) side of EWSR1 is labeled one color (eg, green) and the
other probe specific for the 5 (centromeric) side is labeled a different
color (eg, orange). Subsequently 50 to 200 tumor cell nuclei are evalu-
ated with fluorescence microscopy. Cells with a chromosomal rearran-
gement have two discrete colors distanced from each other indicating
a translocation involving one EWSR1 allele while, the second allele is
intact with two colors (Figure 2). The interpretation of intact and split
signals follows generally accepted guidelines that are used for all com-
mercially available break-apart FISH assays in clinical laboratories. This
requires the space between two signals to be greater than one signal
width in order to be considered a split signal. Depending on the labo-
ratory a result is considered positive when more than 10% to 20% of
the tumor nuclei have evidence of the rearrangement. Nuclear trunca-
tion by the processing and overlapping cells can potentially lead to
false positives; therefore, only tumor cells with all four signals are
analyzed.
A literature review to identify the current scientific evidence
behind the use of COL1A1-PDGFB FISH for the diagnosis of DFSP
as well as dual-color break-apart EWSR1 FISH for the diagnosis of
CCS was performed. Next the scientific evidence for each was
enumerated and summarized. Finally, we utilized an audience
response system during Short Course I “Best Practices” at the 51st
annual meeting of the American Society of Dermatopathology in
Chicago, IL to assess the current utilization patterns of the tests in
attendees.
FIGURE 2 Dual-color, break-apart interphase fluorescence in situ
hybridization (FISH) in clear cell sarcoma. One signal is fused (red and
green = yellow) indicating an intact EWSR1 (22q12) allele whereas the
other signal is split indicating the presence of EWSR1 gene
rearrangement (×200, courtesy of Julia Bridge, MD)
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2 | MATERIALS AND METHODS
2.1 | Literature review
2.1.1 | t(17;22) COL1A1-PDGFB FISH for diagnosis
of DFSP
A search for journal articles written in English was performed in
PubMed using keywords “dermatofibrosarcoma” combined with either
“FISH,” “fluorescence in situ,” “translocation,” “fusion,” “COL1A1,” or
“PDGFB” and a date range from 2000 to present (Table 1). A total of
596 articles were obtained. Titles and abstracts were reviewed and
overlapping studies were filtered out. Articles with relevant data
about the use of FISH for detection of chromosomes 17 and 22 rear-
rangements in DFSP were included. Case series of greater than three
were included if no other evidence was available. A few case reports
discussing unusual variants of DFSP were also included.
We identified 22 papers that evaluated the presence of
COL1A1-PDGFB rearrangement in DFSP, summarized in
Table 1.4–7,15,18,19,43–55 Among the selected studies, half of them
were retrospective case series,15,19,44,48,50–52,54–57 two were prospec-
tive studies,45,46 two were phase II imatinib trials18,47 and seven were
case reports.4–7,43,49,53 The case reports were included because they
described less common variants of DFSP such as pigmented DFSP
(Bednar tumor),43 DFSP in a patient with Cowden Syndrome,53 DFSP
with pleomorphic sarcomatous transformation,7 DFSP with labyrin-
thine plexiform and braided pattern high-grade fibrosarcoma,5,6 and a
vascular variant of DFSP.4 Overall, 853 samples belonging to
830 patients were included in this meta-analysis. As expected, most
tumors were located on the trunk (43.06%) and extremities (39.38%)
with less frequent distribution on the head/neck (12.02%), groin
(1.22%), and axilla (0.12%). Median age across studies varied between
24.5 and 53 years and genders were equally represented (males:
49.8%, females: 50.2%). The distribution of primary tumors, local
recurrences, and metastatic tumors among the cases included in this
meta-analysis was 83.9%, 3.17%, and 1.64%, respectively. In 11.25%
of cases this data were not available. The overall distribution of diag-
noses was as follows: classic DFSP—457 cases (77.45%), DFSP with
fibrosarcomatous transformation—76 cases (12.88%), pigmented
DFSP (Bednar tumor)—7 cases (1.18%), DFSP with GCF component—
9 cases (1.52%), pure GCF—10 cases (1.69%), DFSP with pleomorphic
sarcomatous transformation—5 cases (0.84%), myxoid DFSP—5 cases
(0.84%), DFSP with labyrinthine plexiform high-grade fibrosarcoma—2
cases (0.33%), DFSP with vascular pattern—2 cases (0.3%), sclerotic
DFSP—8 cases (1.35%), DFSP with myoid nodules—4 cases (0.6%),
DFSP mimicking cellular dermatofibroma—2 cases (0.33), and atrophic
DFSP and DFSP with round cell component—1 case each (0.16%).
Data regarding CD34 immunohistochemical staining were available in
11 studies. The frequency of CD34 positive cases ranged between
80% and 100%, with most studies reporting >90% positivity (Support-
ing Information Table S1 and S2).
A total of 13 studies used dual fusion FISH,4–7,43,45–48,50,52,54,55
4 used PDGFB break-apart FISH,15,18,44,53 1 study used COL1A1
break-apart FISH,20 2 studies used both dual fusion and PDGFB
break-apart FISH,49,57 2 studies used both dual fusion FISH and RT-
PCR,19,56 and 1 study used PDGFB break-apart FISH and RT-PCR.51 In
all but two studies (20 studies) a relatively certain diagnosis of DFSP
or variants thereof could be made based on histology and CD34 stain-
ing. In the remaining two studies, the authors separated cases with a
certain diagnosis from those with a probable or possible diagnosis of
DFSP.45,46 Overall, a total number of 582 cases with a relatively cer-
tain diagnosis of DFSP were identified and out of these, dual fusion
FISH and PDGFB break-apart FISH were successfully performed in
441 and 120 cases, respectively.
The overall sensitivity of the dual fusion FISH test, defined as per-
centage of FISH positive cases out of total DFSP cases, was 94.33%,
ranging in various studies from 86% to 100%. For the evaluation of
sensitivity, only cases with a definitive diagnosis of DFSP based on
histology and CD34 expression were considered (441 cases) and cases
with probable or possible diagnosis were excluded. A total of 25 cases
(5.6%) with a certain diagnosis of DFSP were negative for FISH. One
reason could be represented by the low number of translocated cells,
which in some tumors are reported to be as low as 2% and thus can
be easily overlooked.19 Another cause could be the presence of alter-
native rearrangements such as t(5;8).58 A total of four studies on dual
fusion FISH included normal controls allowing for determination of
test specificity defined as percentage of FISH negative cases per total
negative control cases.19,50,52,56 Normal skin, postsurgical scar tissue,
and dermatofibroma were used for normal controls. One study
included colon and lung carcinoma as normal controls56 and another
used dermal dendrocyte hamartoma, a mimic of DFSP.50 In all studies,
the dual fusion FISH test performed with a specificity of 100%. Data
TABLE 1 DFSP literature review summary
Summary of cited articles
Total number of articles: 23
Number of patients/samples 830/853
FISH dual fusion
Sensitivity 416/441 (94.33%)
Specificity 41/41 (100%)
% failed test 61/751 (8.12%)
FISH breakapart
Sensitivity 114/120 (95%)
Specificity N/A
% failed test 4/124 (3.22%)
RT-PCR
Sensitivity 104/143 (72.72%)
Specificity N/A
% failed test 23/130 (17.69%)
Clinical
Male 409/821 (49.81%)
Female 412/821 (50.19%)
Extremities 321/815 (39.38%)
Trunk 351/815 (43.06%)
H&N 98/815 (12.02%)
Groin 10/815 (1.22%)
Axilla 1/815 (0.12%)
Other/unknown 34/815 (4.17%)
Abbreviations: DFSP, dermatofibrosarcoma protuberans; FISH, fluores-
cence in situ hybridization; H&N, head and neck; RT-PCR,
reverse-transcriptase polymerase chain reaction.
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regarding the rate of test failure for dual fusion FISH could be derived
from 10 studies,4–6,19,43,45–47,49,52 which showed an overall test fail-
ure frequency of 8.12%. In most cases, the reason for test failure was
determined to be inappropriate fixation or use of a fixative other than
formalin.46
From the six studies evaluating the PDGFB break-apart FISH test,
the overall sensitivity was 95% (range: 91%-100%). There was no data
available to determine the specificity of the PDGFB break-apart FISH
test. The overall failure rate for this test was 3.22%. Only one study
evaluated the COL1A1 break-apart probe in DFSP with a sensitivity of
100%.20 In three studies, RT-PCR was performed in parallel with
FISH.19,51,56 The overall sensitivity for RT-PCR was 72.53% and the
incidence of failed tests was 17.69%.
In a prospective study by Karanian et al, 448 consecutive tumors
suspected to be DFSP were subjected to FISH testing using dual
fusion FISH.46 All tumors were subclassified as certain (200 cases),
probable (122 cases), and possible DFSP (126 cases). A tumor was
classified as probable DFSP when DFSP was the most likely diagnosis,
but another diagnosis such as cellular dermatofibroma was also con-
sidered. A tumor was classified as possible DFSP when the first con-
sidered diagnosis was not DFSP. The percentage of FISH positive
cases in the cohort of certain DFSP cases was 96%, similar to the sen-
sitivity of the dual fusion FISH test in other studies. However, the per-
centage of FISH positivity dropped to 91% and 19% in the cohorts of
cases with probable and possible DFSP diagnosis, respectively. In the
cohort of cases with a probable DFSP diagnosis, the negative FISH
test resulted in reclassification of 7% of cases from DFSP to another
diagnosis. In the cohort of cases with a possible DFSP diagnosis, the
positive FISH test resulted in reclassification of 19% of cases from
undifferentiated sarcoma, myxofibrosarcoma or benign soft tissue
tumors into classic DFSP or DFSP variants. In another similar prospec-
tive study by Italiano et al, 50 cases of DFSP, classified as certain
(27 cases—54%), probable (7 cases—14%) and possible (16 cases—
32%) were subjected to FISH testing.45 Criteria for diagnosis were
similar to those in the study by Karanian et al: certain—when DFSP
was the only possible diagnosis, probable—when DFSP was the most
probable diagnosis, and possible—when there were other equally
likely diagnoses. While FISH was positive in all cases with a certain
diagnosis, only 86% and 56% of the probable and possible cases
respectively were FISH positive. As a result of molecular studies, three
cases initially classified as benign were reclassified as DFSP and trea-
ted with wide local excision and two undifferentiated sarcomas were
reclassified as DFSP and responded to imatinib therapy.
Two phase II imatinib trials in DFSP correlating the response to
therapy with presence of COL1A1-PDGFB fusion were identified. In a
study by McArthur et al, 10 cases of DFSP were treated with imatinib.
Of these, eight cases were locally advanced cases and two cases were
metastatic cases. FISH was positive in nine cases, all of which demon-
strated either total (four cases) or partial (five cases) response to
therapy. One case was negative by FISH and showed no response to
imatinib.18 In a study by Kerob et al, 21 of 25 DFSP patients with
COL1A1-PDGFB rearrangement 9 (38%) achieved complete or partial
response, while none of the 2 patients without the translocation
responded to imatinib therapy.47
2.2 | Dual color break-apart EWSR1 FISH in
differentiating melanocytic tumors from CCS
Because of the rarity of CCS, the date range was not limited when
performing the literature search for dual-color break-apart EWSR1
FISH for differentiating melanocytic tumors from CCS (Table 2). The
translocation was first identified in 1990. A search for journal articles
written in English was performed in PubMed and only case reports
with scientifically sound evidence of molecular testing were included.
Articles addressing visceral CCS (gastrointestinal, pulmonary, and
renal) were excluded.
We identified 18 relevant articles, all retrospective studies, that
are summarized in Table 2.30,31,33,34,36,40,59–70 The overall number of
patients was 234, which included 236 samples analyzed. As expected,
a significant proportion of cases were from acral sites (46.67%,
91/195) and the majority of patients (83%) were less than 50 years of
age (171/206). Only a few cases reported the sarcoma having a com-
ponent “mimicking junctional nests”; one case remarked on a junc-
tional component.37 Most series used melanoma cases or melanoma
cell lines as negative controls with the exception of one study that
compared many different types of sarcoma.24 The overall sensitivity
of dual-color break-apart EWSR1 FISH was 88.89% and the specificity
97.91%; the test failed for various reasons in 6.33% of cases. The sen-
sitivity of the dual fusion test was 60%, whereas its specificity was
100%. There were no data available regarding the percentage of failed
TABLE 2 CCS literature review summary
Summary of cited articled
Total of articles: 18
Number of patients/samples: 234/236
FISH dual fusion
Sensitivity 60%
Specificity 100%
% failed test N/A
FISH breakapart
Sensitivity 88.89%
Specificity 97.91%
% failed test 6.33%
RT-PCR
Sensitivity 91.61%
Specificity 100%
% failed test 22.22%
Clinical
Acral 91/195 (46.67%)
<50 years old 171/206 (83%)
Other findings
• Most series used melanoma cases or melanoma cell lines as
negative controls for tests (except one study which compared many
different types of sarcoma)
• Few cases reported with areas “mimicking junctional nests”, one
case with reported junctional component
• BRAF mutation + in 4.55% cases, NRAS mutation + in 4.55% cases
• One study looked at deep tumors previously called melanoma and
found EWSR1 rearrangements in 2 of 18 cases (11.11%)
Abbreviations: CCS, clear cell sarcoma; FISH, fluorescence in situ hybridi-
zation; RT-PCR, reverse-transcriptase PCR.
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tests. The sensitivity for RT-PCR was 91.61% and the specificity was
100%; RT-PCR failed in 22.22% of cases.
In one of the first series after the discovery of the translocation,
where FISH or RT-PCR was not performed, conventional karyotypes
were positive for t(12;22)(p11.2;p11.2) in one case and t(12;22)(q13;
q13) in another case out of five in total.58 Two other cases displayed
chromosome 22 abnormalities without a definitive translocation iden-
tified. This series exemplifies the low yield or negative predictive value
(NPV) of conventional cytogenetic karyotyping as well as the difficul-
ties in ascertaining precise location of chromosomal rearrangements.
This study also demonstrated that none of the CCS cases displayed
microsatellite instability (MSI). One CCS case did have loss of hetero-
zygosity of 9p21, raising the question if the lesion should be better
classified as a melanocytic/spitzoid tumor.
Another study described two purely cutaneous cases.31 Six cases
were entirely dermal, whereas the other six showed invasion of the
subcutis. In six cases, the nests bordered the epidermis mimicking
junctional nests of melanocytes although “true nests” were not identi-
fied. Falconieri et al also reported three cases of dermal CCS with min-
imal extension to the subcutis all of which were confirmed by EWSR1
FISH.36
In one other large study from a tertiary center, FISH and RT-PCR
results on a variety of sarcoma cases, including CCS, were reviewed.64
The study highlights the difficulties that arise when the methods of
tissue fixation and processing of referral blocks are not certain result-
ing in higher RT-PCR failure rates.
Song et al subjected 18 cases with malignant melanoma diagnosis
from non-cutaneous, deeply located sites and unknown primary sites
to break-apart EWSR1 FISH.65 They identified two patients with
EWSR1 gene rearrangement with a mean of 67.5% positive cells per
sample re-classifying them as CCS. The cases were subsequently vali-
dated using RT-PCR identifying the presence of type I (EWSR1
exon8-ATF1 exon 4) fusion transcripts. Retrospective analysis
revealed that the masses were located in the foot and buttock.
In a retrospective study of 52 patients with CCS, Hocar
et al identified 1 of 22 tested cases with a BRAF mutation and 1 of
22 tested cases with a NRAS mutation33; both cases were confirmed
using RT-PCR. Park et al also described two cases of CCS, one dermal,
and one subcutaneous, which were confirmed using FISH and RT-
PCR.34 BRAF mutation was detected in the dermal type and KIT muta-
tion in the subcutaneous one raising interesting questions regarding
treatment options.
Lastly, Ito et al reported an exceedingly rare case of CCS in the
penis68 whereas Feasel et al described three cases in the head and
neck expanding the anatomic distribution.69
2.3 | Survey of current utilization
During the 51st annual meeting of the ASDP in Chicago, IL, an audi-
ence response system surveyed attendees of short course I “Best
Practices” regarding their current utilization of t(17;22)
COL1A1-PDGFB dual fusion FISH for the diagnosis of DFSP and
EWSR1 break-apart FISH in differentiating melanocytic tumors from
CCS. The audience was polled prior to the presentation of the
literature overview for their overall current utilization and after for
the utilization of the specific ancillary studies in a case setting
presentation.
3 | COMMENTS AND CONCLUSIONS
3.1 | Current utilization
An audience response system was used to identify the current utiliza-
tion patterns of ordering FISH for DFSP and CCS. Basic demographic
information of the participants revealed that the majority of respon-
dents are in an academic practice setting (47%). There was a relatively
even distribution of experience in dermatopathology with 36% in
training, 23% practicing less than 5 years, 22% practicing 5-10 years,
and 19% practicing more than 15 years. The majority of respondents
were from the United States (93%) with the highest representation
from the Central region (36%). There were between 81 and
105 unique participants that responded to the various queries for the
soft tissue portion of the presentation. The majority of responders
(38%) send FISH testing out to an academic (27%) or a commercial
(11%) referral laboratory. Only 35% of participants have FISH avail-
able in-house at their academic (22%) or commercial (5%) laboratory.
Of note, 37% send their entire case for an outside consultation if it
needs or may need FISH; meaning if they do not perform the FISH in
house and they also do not order the test in isolation. The majority of
participants (51%) are diagnosing DFSP in their practice approximately
1 to 2 times in 1 year. Of note, the audience responses showed that
participants were more likely to order FISH for distinguishing melano-
cytic lesions from CCS. Respondents (69%) would order FISH with an
additional 17% ordering FISH after contacting the referring clinician
and obtaining clinician/insurance/patient approval. Conversely, only
21% would order FISH for DFSP with an additional 16% of respon-
dents ordering the study after contacting the referring clinician and
getting clinician/insurance/patient approval.
3.2 | t(17;22) COL1A1-PDGFB FISH for the diagnosis
of DFSP
The reviewed evidence demonstrates that FISH is a sensitive and spe-
cific diagnostic test for DFSP. The sensitivity of the dual fusion and
PDGFB break-apart FISH appears to be similar (94% and 95%, respec-
tively). The sensitivity of the COL1A1 break-apart probe is probably in
the same range; however, only one study explicitly mentioning this
probe was identified. The specificity of the dual fusion FISH test was
100%. No data was found about the specificity of the break-apart
FISH tests. The overall percentage of failed tests was about 8% for
the dual fusion FISH probe and 3% for the break-apart PDGFB FISH
test. The lower rate of failed tests for the break-apart vs dual fusion
FISH could be related to the lower complexity of the former FISH test
with only two probes flanking a gene vs the latter with at least four
probes flanking two genes which increases the likelihood that one or
more probes will fail hybridization. However, the difference could also
be related to differences in study format. In the series of studies on
break-apart FISH, only one study explicitly reported the failure rate vs
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four studies reporting this information in the dual fusion FISH cohort.
As expected, RT-PCR showed a lowered sensitivity (73%) and higher
rate of failed tests (18%) compared to FISH, probably due to the chal-
lenges in obtaining good quality RNA from formalin-fixed paraffin-
embedded material.
The data suggests that FISH testing has limited value in classic
DFSP as the overwhelming majority would be positive for
COL1A1-PDGFB rearrangements if the test is performed. This is
reflected in the current practice as the majority of responders sur-
veyed during the ASDP short course would not order FISH testing to
support a diagnosis of classic DFSP. However, FISH testing is useful in
circumstances where a definitive diagnosis cannot be made based on
histology and CD34 staining. Benign tumors such as deep or cellular
dermatofibromas can be confused with DFSP, especially in limited
biopsies and in this instance a negative FISH test can support the cor-
rect diagnosis and prevent over- or under-treatment. Unusual variants
of DFSP may mimic other sarcomas such as fibrosarcoma, undifferen-
tiated pleomorphic sarcoma or myxofibrosarcoma and in these
instances FISH testing can be instrumental in accurate classification.
Finally, there is data supporting the use of FISH testing to predict
response to treatment with imatinib. In summary, FISH testing (either
dual fusion or break-apart), when used judiciously, can be a valuable
tool in correctly diagnosing and managing DFSP.
3.3 | EWSR1 break-apart FISH in differentiating
melanocytic tumors from CCS
The review of the literature indicates that the fusion (either EWS-
R1-ATF1 or EWSR1-CREB1) is present in the majority of cases of CCS,
whereas no melanomas were identified to harbor these translocations.
Given the high sensitivity and specificity of the dual-color break-apart
FISH test in this clinical scenario and the significant consequences of
a misdiagnosis the literature supports the use of dual-color break-
apart EWSR1 FISH to differentiate CCS from melanoma or other
melanocytic neoplasms. This is reflective of the current practice of
respondents attending the short course as the majority (69%) would
order the test to support the diagnosis with an addition 17% doing so
after contacting the referring clinician.
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